Galderma Group Valuation
Is GALD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GALD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GALD (CHF85.18) is trading below our estimate of fair value (CHF192.15)
Significantly Below Fair Value: GALD is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GALD?
Key metric: As GALD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GALD's PS Ratio? | |
|---|---|
| PS Ratio | 5.3x |
| Sales | US$4.32b |
| Market Cap | US$22.78b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.9x |
| Enterprise Value/EBITDA | 30.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does GALD's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
SDZ Sandoz Group | 1.9x | 5.7% | CHF 17.5b |
DESN Dottikon ES Holding | 9.6x | 14.5% | CHF 3.2b |
NOVN Novartis | 4.1x | 2.2% | CHF 182.4b |
ROG Roche Holding | 3.3x | 3.9% | CHF 203.6b |
GALD Galderma Group | 5.3x | 11.6% | CHF 20.2b |
Price-To-Sales vs Peers: GALD is expensive based on its Price-To-Sales Ratio (5.3x) compared to the peer average (4.8x).
Price to Sales Ratio vs Industry
How does GALD's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: GALD is expensive based on its Price-To-Sales Ratio (5.3x) compared to the European Pharmaceuticals industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is GALD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.3x |
| Fair PS Ratio | 6.2x |
Price-To-Sales vs Fair Ratio: GALD is good value based on its Price-To-Sales Ratio (5.3x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 85.18 | CHF 89.49 +5.1% | 8.0% | CHF 105.87 | CHF 79.12 | n/a | 11 |
| Nov ’25 | CHF 81.44 | CHF 89.49 +9.9% | 8.0% | CHF 105.87 | CHF 79.12 | n/a | 11 |
| Oct ’25 | CHF 77.61 | CHF 82.53 +6.3% | 9.5% | CHF 102.40 | CHF 72.86 | n/a | 11 |
| Sep ’25 | CHF 82.30 | CHF 79.93 -2.9% | 7.6% | CHF 90.06 | CHF 70.28 | n/a | 10 |
| Aug ’25 | CHF 69.09 | CHF 77.33 +11.9% | 5.0% | CHF 82.41 | CHF 71.02 | n/a | 8 |
| Jul ’25 | CHF 72.11 | CHF 78.75 +9.2% | 4.8% | CHF 83.81 | CHF 70.73 | n/a | 8 |
| Jun ’25 | CHF 73.27 | CHF 78.21 +6.7% | 4.3% | CHF 81.95 | CHF 71.43 | n/a | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Gerresheimer
€2.5b
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€75.60
7D
0%
1Y
0%
Roche Holding
CHF 203.6b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
ROG
CHF 253.50
7D
-4.5%
1Y
6.9%
Bristol-Myers Squibb
US$100.3b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$54.24
7D
0%
1Y
0%